Novartis solid tumor 'CAR T cell' still holds promise: researcher

April 20, 2015 9:49 PM

3 0

Novartis solid tumor 'CAR T cell' still holds promise: researcher

(Reuters) - A new type of immuno-oncology treatment from Novartis AG proved safe in a tiny study of three types of solid tumors, but the trial included too few patients and used too small a dose of the experimental product to prove effectiveness, according to data presented at a cancer meeting on Sunday.

The so-called CAR T cell is among a wave of new cancer treatments created by removing T cells, powerful immune system cells, from a patient's body and attaching an antibody fragment that enables them to recognize and target specific proteins on cancer cells. The souped-up T cells are then reinfused ...

Read more

To category page

Loading...